Factor analysis of the French version of the shorter 12-item Perception of Aggression Scale (POAS) and of a new modified version of the Overt Aggression Scale (MOAS)

2012 ◽  
Vol 19 (10) ◽  
pp. 875-880 ◽  
Author(s):  
L. DE BENEDICTIS ◽  
A. DUMAIS ◽  
M.-C. STAFFORD ◽  
G. CÔTÉ ◽  
A. LESAGE
Keyword(s):  
Factor Analysis ◽  
Overt Aggression ◽  
French Version ◽  
Overt Aggression Scale

The French Version of the Revised Child Anxiety and Depression Scale (RCADS) in a Nonclinical Sample

2015 ◽  
Vol 74 (3) ◽  
pp. 119-127 ◽  
Author(s):  
Martine Bouvard ◽  
Anne Denis ◽  
Jean-Luc Roulin
Keyword(s):  
Factor Analysis ◽  
Anxiety Disorder ◽  
Confirmatory Factor Analysis ◽  
Generalized Anxiety Disorder ◽  
Child Anxiety ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Generalized Anxiety ◽  
French Version ◽  
Confirmatory Factor

This article investigates the psychometric properties of the Revised Child Anxiety and Depression Scale (RCADS). A group of 704 adolescents completed the questionnaires in their classrooms. This study examines potential confirmatory factor analysis factor models of the RCADS as well as the relationships between the RCADS and the Screen for Child Anxiety Related Emotional Disorders-Revised (SCARED-R). A subsample of 595 adolescents also completed an anxiety questionnaire (Fear Survey Schedule for Children-Revised, FSSC-R) and a depression questionnaire (Center for Epidemiological Studies Depression Scale, CES-D). Confirmatory factor analysis of the RCADS suggests that the 6-factor model reasonably fits the data. All subscales were positively intercorrelated, with rs varying between .48 (generalized anxiety disorder-major depression disorder) and .65 (generalized anxiety disorder-social phobia/obsessive-compulsive disorder). The RCADS total score and all the RCADS scales were found to have good internal consistency (> .70). The correlations between the RCADS subscales and their SCARED-R counterparts are generally substantial. Convergent validity was found with the FSSC-R and the CES-D. The study included normal adolescents aged 10 to 19. Therefore, the findings cannot be extended to children under 10, nor to a clinical population. Altogether, the French version of the RCADS showed reasonable psychometric properties.

Overt Aggression Scale

1986 ◽  
Author(s):  
Stuart C. Yudofsky ◽  
Jonathan M. Silver ◽  
Wynn Jackson ◽  
Jean Endicott ◽  
Daniel Williams
Keyword(s):  
Overt Aggression ◽  
Overt Aggression Scale

scholarly journals Violent behaviour in schizophrenia

2005 ◽  
Vol 187 (5) ◽  
pp. 426-430 ◽  
Author(s):  
Jan Vevera ◽  
Alan Hubbard ◽  
Arnošt Veselý ◽  
Hana Papežová
Keyword(s):  
Logistic Regression ◽  
Substance Misuse ◽  
Overt Aggression ◽  
Psychotic Symptoms ◽  
Violent Behaviour ◽  
Stable Conditions ◽  
Dsm Iv ◽  
Available Information ◽  
Overt Aggression Scale ◽  
Over Time

BackgroundA number of studies have reported increased violence in patients with schizophrenia.AimsTo determine the prevalence of violence among those with schizophrenia in samples from 1949, 1969, 1989 and 2000 in Prague (Czech Republic) and to examine trends in this behaviour.MethodRecords from 404 patients meeting DSM–IV criteria for schizophrenia were screened for violence (defined as 3 points on the Modified Overt Aggression Scale) from the first observed psychotic symptoms until the time of latest available information.ResultsLogistic regression revealed a marginally significant increase in violence only inthe 2000 cohort. Overall, violence was associated with schizophrenia in 41.8% of men and 32.7% of women, with no association between substance misuse and violence.ConclusionsThe violence rate found in our sample is expected to remain stable over time under stable conditions. Substance misuse is not the leading cause of violence among those with schizophrenia.

scholarly journals Estudio farmacogenómico en Trastorno Límite de Personalidad.

2013 ◽  
Vol 71 (1-4) ◽  
pp. 58-64
Author(s):  
Hernán Silva ◽  
Patricia Iturra ◽  
Aldo Solari ◽  
Juana Villarroel ◽  
Sonia Jerez ◽  
...  
Keyword(s):  
Overt Aggression ◽  
Overt Aggression Scale

Antecedentes: Las conductas agresivas e impulsivas han sido asociadas con disfunciones del sistema serotoninérgicocentral. Polimorfismos del transportador de serotonina, de la triptófano hidroxilasa (TPH1) y de los receptoresserotoninérgicos 5HT1B y 5HT2C han sido vinculados a agresión e impulsividad. Varios estudios en depresiónmayor han demostrado que el alelo corto (S) del promotor del gen transportador de serotonina se asocia a una peorrespuesta a los inhibidores selectivos de la recaptación de serotonina (ISRS). Material y métodos: En este estudiose investigó la asociación entre la respuesta de la impulsividad al tratamiento con fluoxetina y polimorfismos deltransportador de serotonina, TPH1 y de los receptores 5HT1B y 5HT2C, en 49 pacientes con trastorno límite depersonalidad. Resultados: Los pacientes con el genotipo L/L del promotor del gen transportador de serotonina,evaluados mediante la Overt Aggression Scale-Modified (OAS-M), tuvieron una respuesta a fluoxetinasignificativamente mejor que los portadores del alelo S. No se encontró asociación entre la respuesta a fluoxetina ylos genotipos de TPH1 y de los receptores 5HT1B y 5HT2C. Conclusiones: Este es el primer estudio en el que seevalúa la asociación entre estos polimorfismos y la respuesta anti-impulsiva a la fluoxetina en pacientes con trastornolímite de personalidad. El alelo S puede representar un factor común de peor respuesta a los ISRS en enfermedadesasociadas a una disfunción serotoninérgica. (Rev. Neuropsiquiatría 2008; 71: 58-64).

scholarly journals Validation of the French Version of the Auditory Hallucination Rating Scale in a Sample of Hallucinating Patients with Schizophrenia

2019 ◽  
Vol 65 (4) ◽  
pp. 237-244 ◽  
Author(s):  
Clément Dondé ◽  
Frédéric Haesebaert ◽  
Emmanuel Poulet ◽  
Marine Mondino ◽  
Jérôme Brunelin
Keyword(s):  
Factor Analysis ◽  
Rating Scale ◽  
Auditory Hallucination ◽  
Intraclass Correlation ◽  
Internal Validity ◽  
Correlation Coefficients ◽  
French Version ◽  
Fine Grained ◽  
French Speaking ◽  
Item Scores

Objective: The aim of this study was to validate the French version of the 7-item Auditory Hallucination Rating Scale (AHRS) so as to facilitate fine-grained assessment of auditory hallucinations (AH) in native French-speaking patients with schizophrenia (SZ) in clinical settings and studies. Method: Patients ( N = 66) were diagnosed with SZ according to the Diagnostic and Statistical Manual of Mental Disorders. The French version of the AHRS was developed using a forward–backward translation procedure. Psychometric properties of the French version of the AHRS were tested including (i) construct validity with a confirmatory one-factor analysis, (ii) internal validity with Pearson correlations and Cronbach α coefficients, and (iii) external validity by correlations with the Scale for Assessment of Positive Symptoms (SAPS-H1), the Positive and Negative Syndrome Scale (PANSS-P3; concurrent), the PANSS-Negative subscale and age of subjects (divergent), and inter-rater intraclass correlation coefficients (ICCs). Results: (i) The confirmatory one-factor analysis found a root mean square error of approximation (RMSEA) = 0.00, 90% confidence interval = [0.000 to 0.011], and a comparative fit index = 0.994. (ii) Correlations between AHRS total score and individual items were mostly ≥0.4. Cronbach α coefficient was 0.61. (iii) Correlations with PANSS-P3 and SAPS-H1 were 0.42 and 0.53, respectively. In a subset of participants ( N = 16), ICC values were extremely high and significant for AHRS total and individual item scores (ICCs range 0.899 to 0.996) Conclusion: The French version of the AHRS is a psychometrically acceptable instrument for the evaluation of AH severity in French-speaking patients with SZ.

scholarly journals Validation of the French Version of the MacArthur Competence Assessment Tool for Treatment (MacCAT-T) in a French Sample of Individuals with Schizophrenia: Validation de la version française de l’instrument d’évaluation des compétences MacArthur-traitement (MacCAT-T) dans un échantillon français de personnes souffrant de schizophrénie

2020 ◽  
pp. 070674372096644
Author(s):  
Stéphane Raffard ◽  
Cindy Lebrun ◽  
Yasmine Laraki ◽  
Delphine Capdevielle
Keyword(s):  
Decision Making ◽  
Factor Analysis ◽  
Assessment Tool ◽  
Competence Assessment ◽  
Rater Reliability ◽  
French Version ◽  
Capacity To Consent ◽  
Decision Making Capacity ◽  
Consent To Treatment ◽  
High Degree

Background: Assessing an individual’s capacity to consent to treatment is a complex and challenging task for psychiatrists and health-care professionals. Diminished capacity to consent to pharmacological treatment is a common concern in individuals with schizophrenia. The MacArthur Competence Assessment Tool for Treatment (MacCAT-T) is the most common tool used in individuals with schizophrenia to evaluate the decision-making abilities for judgments about competence to consent to treatment. This instrument assesses patients’ competence to make treatment decisions by examining their capacities in 4 areas: understanding information relevant to their condition and the recommended treatment, reasoning about the potential risks and benefits of their choices, appreciating the nature of their situation and the consequences of their choices, and expressing a choice. Despite its importance, there is no French version of this scale. Furthermore, its factor structure has never been explored, although validated measures are strongly needed to further detect deficits in patients’ decision-making abilities. The goal of this study was thus to empirically validate a French version of the MacCAT-T in a French sample of individuals with schizophrenia. Method: In this cross-sectional study, we included 125 inpatients with a diagnosis of schizophrenia from the University Department of Adult Psychiatry in Montpellier. The MacCAT-T was administered to patients by a trained psychologist. Patients were also assessed for severity of symptoms, insight into illness, and depressive and anxiety symptoms. Inter-rater reliability and psychometric properties including internal consistency, construct validity, and discriminant and divergent validity were also investigated. Results: The MacCAT-T’s internal consistency was high (Cronbach α of 0.91). A high degree of inter-rater reliability was found for all the areas of the MacCAT-T (intraclass correlation coefficient range, 0.92 to 0.98). Exploratory factor analysis revealed a 2-factor model. The factor analysis explained 50.03% of the total score variation. Component 1 included all subparts of “understanding.” Component 2 included all subparts of “appreciation” and “reasoning” and was therefore labeled “reflexivity.” After Bonferroni corrections, decision-making capacity was positively associated with insight and the severity of psychotic symptoms but not with sociodemographic variables except for education. Conclusions: The MacCAT-T demonstrated a high degree of inter-rater reliability and strong psychometric properties. The French version of the MacCAT-T is a valid instrument to assess the decision-making capacity to consent to treatment in a French sample of individuals with schizophrenia.

An Open-Label Trial of Divalproex Extended-Release in the Treatment of Borderline Personality Disorder

CNS Spectrums ◽  
2007 ◽  
Vol 12 (6) ◽  
pp. 439-443 ◽  
Author(s):  
Daphne Simeon ◽  
Bryann Baker ◽  
William Chaplin ◽  
Ashley Braun ◽  
Eric Hollander
Keyword(s):  
Global Assessment ◽  
Extended Release ◽  
Borderline Personality ◽  
Overt Aggression ◽  
Intensity Measure ◽  
Global Assessment Scale ◽  
Aggression Questionnaire ◽  
Affective Lability ◽  
Affective Intensity ◽  
Overt Aggression Scale

ABSTRACTIntroduction:Borderline personality disorder (BPD) is associated with several symptoms, including impulsivity, aggression, and intense unstable affect, which can be targeted with anticonvulsant agents. Divalproex extended-release (ER) is used widely in clinical practice, which leads to the question of its efficacy and tolerability in treating BPD.Methods:This study assessed the efficacy and tolerability of divalproex ER in 20 adult outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition BPD via a 12-week openlabel trial. Primary outcome measures included the Clinical Global Impression–Improvement (CGI-I) scale and the Global Assessment Scale. Secondary outcome measures assessed aggression (Aggression Questionnaire, Overt Aggression Scale-Modified); affective disturbance (Affective Intensity Measure, Affective Lability Scale); dissociation (Dissociative Experiences Scale); and general psychopathology (Symptom-Checklist 90–Revised).Results:Thirteen subjects were male and seven were female with a mean age of 37.0±11.3 years. Treatment was associated with statistically significant improvement on the CGI-I, the Global Assessment Scale, the Overt Aggression Scale–Modified irritability subscale, and the Aggression Questionnaire. A trend toward significant improvement was observed on the Affective Intensity Measure. Seven out of 10 completers (70%) were treatment responders, with an endpoint CGI-I of 2 (much improved) or 1 (very much improved). There was no significant decline in affective lability or in dissociation. One participant discontinued treatment due to adverse events.Conclusion:These findings support that divalproex ER is an efficacious and well-tolerated pharmacologic agent for BPD, with the additional advantage of single daily dosing at bedtime. Placebo-controlled trials are needed for replication.

Sign in / Sign up

Export Citation Format

Share Document